The timeline depends on the medication, dose, length of treatment, and individual response
Naini AE, Moradi M, Mortazavi M, Amini Harandi A, Hadizadeh M, Shirani F, et al
Yes, BPC-157 can be taken orally for gut health, but its use remains experimental
It is the primary site of insulin-mediated glucose disposal, meaning that losing it worsens the very insulin resistance that GLP-1 therapy is designed to improve
Key findings Related Stories GLP-1 weight-loss drugs may also reduce binge eating Popular diabetes drugs do not alter the risk of developing a blinding eye condition Cleveland Clinic study links gut microbe byproduct to heart arrhythmia Within six months of starting GLP-1 therapy, the rate of hypotensive events increased from 8.7% to 10.2% The increased risk remained significant at 12 months, with hypotensive events rising from 13.6% to 14.3% Adults age 65 and older accounted for 53% of hypotensive events despite representing 37% of the study population Patients with Type 2 diabetes made up 75% of those experiencing hypotensive episodes but only 63% of the overall cohort In secondary analyses, the scientists found that weight loss alone did not explain the increased risk, suggesting other mechanisms of action may be at play Below is a Q&A with study senior author Dr
